Growth hormone (GH) response to GH-releasing hormone (GHRH) in asthmatic patients during long-term inhaled corticosteroids (ICS) treatment

M. Malerba, S. Bossoni, A. Radaeli, C. Lecchi, A. Giustina, A. Burattin, V. Grassi, C. Tantucci (Brescia, Italy)

Source: Annual Congress 2003 - Asthma: potpourri
Session: Asthma: potpourri
Session type: Thematic Poster Session
Number: 2691
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Malerba, S. Bossoni, A. Radaeli, C. Lecchi, A. Giustina, A. Burattin, V. Grassi, C. Tantucci (Brescia, Italy). Growth hormone (GH) response to GH-releasing hormone (GHRH) in asthmatic patients during long-term inhaled corticosteroids (ICS) treatment. Eur Respir J 2003; 22: Suppl. 45, 2691

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Association of adrenal response in asthmatic children on inhaled steroids with polymorphisms in the genes of glucocorticoid receptor (GR) and corticotropin releasing hormone receptor 1 (CRHR1)
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009


Anabolic effects and safety assessments of TH9507, a growth hormone releasing factor (GRF) analog, in patients with COPD-associated wasting
Source: Eur Respir J 2004; 24: Suppl. 48, 292s
Year: 2004

Effects of TH9507, a growth hormone releasing factor (GRF) analog, on functional performance in patients with COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 245s
Year: 2004

Relationship between structural bone changes assessed by ultrasound bone densitometry (UBD) and growth hormone (GH) during chronic treatment with inhaled corticosteroids (ICS) in asthmatic patients
Source: Eur Respir J 2003; 22: Suppl. 45, 419s
Year: 2003

Prevalence of subnormal adrenal responses to low dose synthetic ACTH (synacthen) in children receiving ≥ 500 mcg daily of the inhaled steroid fluticasone propionate (FP)
Source: Eur Respir J 2003; 22: Suppl. 45, 310s
Year: 2003

Salivary cortisol for assessment of hypothalamic-pituitary-adrenal (HPA) axis function in asthmatic children on inhaled corticosteroids (ICS)
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011

Utility of salivary cortisol in corticotropin releasing hormone (CRH) test in asthmatics
Source: Annual Congress 2013 –Uncontrolled and severe asthma in children
Year: 2013

A low-dose (1.0 mcg) rapid ACTH test and adrenal function in adult patients with bronchial asthma treated with inhaled corticosteroids
Source: Eur Respir J 2007; 30: Suppl. 51, 69s
Year: 2007

Using hormone replacement therapy in perimenopausal women with bronchial asthma (BA)
Source: Annual Congress 2007 - Novel issues in the treatment and control of asthma
Year: 2007


Prognostic value of cortisol and adrenocorticotropic hormone (ACTH) in severe community-acquired pneumonia (SCAP) patients
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011


One year vitamin D and parathyroid hormone influence in patients with OSAS and CPAP treatment
Source: International Congress 2018 – Treatments that can serve as an alternative to positive airway pressure (PAP)
Year: 2018


Reduced bone density in inhaled corticosteroids-treated asthmatic patients showing decreased cortisol response to low-dose ACTH test
Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma
Year: 2008

Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids
Source: Eur Respir J 2006; 27: 511-516
Year: 2006



Anti-inflammatory effect of montelukast (ML) and inhaled steroids (ICS) on clinical parameters and serum levels of NO in asthmatic children
Source: Eur Respir J 2003; 22: Suppl. 45, 132s
Year: 2003

Combination of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA) versus similar ICS dose in children and adults with persistent asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

Real-life use and impact of inhaled steroids (ICS) and leukotriene receptor antagonists (LTRA) monotherapy in children with asthma
Source: Annual Congress 2010 - Paediatric asthma treatment and monitoring
Year: 2010

Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids
Source: Eur Respir J 2008; 32: 1047-1052
Year: 2008



Growth hormone releasing hormone receptor (GHRH-R) antagonist MIA-602 modulates fibrosis and gene expression in lungs of bleomycin-treated mice
Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia
Year: 2019


First choice in persistent asthma: inhaled corticosteroids (ICS) or ICS + long-acting beta2-agonist (LABA) combination in steroid-naïve patients?
Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids
Year: 2004


Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma
Source: International Congress 2017 – Techniques to treat asthma
Year: 2017